Acadia Pharmaceuticals (ACAD +10.1%) gets a big bump on a notable mention from Jim Cramer last Friday CNBC's on Mad Money. "This is the real deal," He says. "There was some profit taking this week, but you should hold onto it. ACAD is a fantastic spec." Additionally, Seeking Alpha contributor Brian Nichols added his two cents as well, calling the stock the safest bet in the biotech space right now after Pimavanserin's encouraging Phase 3 trial results.